Navigation Links
Unilens Vision Reports 70% Increase in Second Quarter Earnings on Higher Sales and Record Royalty Income
Date:2/26/2008

LARGO, Fla., Feb. 26 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF) (TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the second quarter and first half of FY2008.

Net sales, excluding royalty income, for the quarter ended December 31, 2007 increased to $1,512,361 compared with $1,438,153 in the quarter ending December 31, 2006, an increase of 5.2%. The increase was primarily the result of continued growth of the Company's C-Vue multifocal contact lenses, which increased approximately 12% in the current quarter, which was partially offset by sales of our replacement products lines that declined as expected.

Net Income for the quarter increased 70.2% to a record second quarter of $375,915, or $0.08 per diluted share, compared with $220,850, or $0.05 per diluted share in the prior-year period.

Royalty income for the quarter increased 20.3% to a record second quarter of $646,849 compared with $537,653 in the prior-year quarter. Sales of licensed products by our licensee Bausch & Lomb continue to accelerate, resulting in the record quarterly royalty payment.

Income before taxes for the quarter ended December 31, 2007 increased 51.1% to $542,257, compared with $358,891 in the prior-year quarter. After recording income tax expense of $166,342, Unilens reported net income of $375,915, or $0.08 per diluted share. In the second quarter of FY2007, the Company reported net income of $220,850, or $0.05 per diluted share, after recording income tax expense of $138,041.

"We are pleased with our second quarter operating results, and based on currently available information, we anticipate a continuation of favorable revenue and profitability trends for the second half of the 2008 fiscal year," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc. "Sales of our C-Vue brand disposable multifocal and single vision lenses continued to achieve double digit growth as did Bausch & Lomb's sales of their multifocal lenses that utilize our proprietary licensed technology, resulting in record royalty income for the Company in the second quarter."

"I am also pleased to report that we will pay our sixth consecutive regular quarterly cash dividend of $0.09 per share, in accordance with a dividend policy adopted by our Board of Directors that is intended to allow our shareholders to share directly in the Company's future earnings growth," concluded Mr. Pecora. The Company's regular quarterly cash dividend will be paid on February 28, 2008 to shareholders of record at the close of business on February 14, 2008.

For the six months ended December 31, 2007, net sales excluding royalty income, increased 4.7% to $3,185,722, as compared to $3,042,929 for the prior- year period. Net sales of the Company's C-Vue multifocal contact lenses increased approximately 11.5% during the first half of fiscal year 2008, while sales of replacement products lines declined, as expected.

Net Income for the six months increased 41.8% to $753,211, or $0.17 per diluted share, compared with $531,342, or $0.12 per diluted share in the prior-year period.

Royalty income for the six months ended December 31, 2007 increased 24.2% to a record $1,259,648, compared with $1,014,203 in the prior-year period, demonstrating accelerated demand for sales of licensed products by our licensee Bausch & Lomb.

Income before taxes for the six months ended December 31, 2007 increased 32.6% to $1,158,758, compared with $874,074 in the prior-year period. After recording net income tax expense of $405,457, Unilens reported net income of $753,211, or $0.17 per diluted share, for the six months ended December 31, 2007. This compared with net income of $531,342, or $0.12 per diluted share, in the prior-year period of fiscal year 2007, which included net income tax expense of $342,732.

About Unilens Vision Inc. - "The Eye Care Professionals Specialty Contact Lens Company"

Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets specialty contact lenses under the C- Vue, Unilens, Sof-Form, Aquaflex, SoftCon, Lombart, and LifeStyle brands. Additional information on the Company may be accessed on the Internet at http://www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI".

(Note: All financial information in this release is stated in U.S. Dollars.)

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward- looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Leonard F. Barker, CFO, Unilens Vision Inc. at (727) 544-2531

UNILENS VISION INC.

SECOND QUARTER AND SIX MONTHS - FISCAL 2008

CONDENSED CONSOLIDATED FINANCIAL INFORMATION

(All figures in U.S. Dollars)

RESULTS OF OPERATIONS

Three Months Three Months Six Months Six Months

Ended Ended Ended Ended

December 31, December 31, December 31, December 31,

2007 2006 2007 2006

Sales $1,512,361 $1,438,153 $3,185,722 $3,042,929

Cost of sales 885,453 883,829 1,789,850 1,714,459

626,908 554,324 1,395,872 1,328,470

Expenses 715,190 735,645 1,470,142 1,488,352

Loss from operations (88,282) (181,321) (74,270) (159,882)

Other items:

Royalty income 646,849 537,653 1,259,648 1,014,203

Other (expense) income (21,775) (677) (48,916) 313

Remeasurement income

(loss) 471 (5,306) 3,012 (1,929)

Interest income 4,994 8,542 19,284 21,369

630,539 540,212 1,233,028 1,033,956

Income before tax 542,257 358,891 1,158,758 874,074

Income tax expense 166,342 138,041 405,547 342,732

Net income for the

period $375,915 $220,850 $753,211 $531,342

Net income per common

share:

Basic $0.08 $0.05 $0.17 $0.12

Diluted $0.08 $0.05 $0.17 $0.12

CASH FLOWS

Provided (used) by:

Operating activities $265,988 $447,670 $955,246 $778,354

Investing activities (1,636) (51,829) (29,759) (89,954)

Financing activities (409,564) (334,470) (2,153,572) (1,448,388)

(Decrease) increase

in cash $(145,212) $61,371 $(1,228,085) $(759,988)

BALANCE SHEET

June 30, December 31, December 31,

2007 2007 2006

Cash 1,961,712 $736,639 $1,433,716

Total assets 7,987,808 6,331,743 7,849,747

Current liabilities 819,005 563,301 794,581

Total liabilities 819,005 563,301 794,581

Stockholders' equity 7,168,803 $5,768,442 $7,055,166


'/>"/>
SOURCE Unilens Vision Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens
2. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
3. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
4. Vision restoration therapy shown to improve brain activity in brain injured patients
5. Mouse vision has a rhythm all its own
6. HEI, Inc. Announces Sale of RFID Division Assets
7. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
8. The aye-ayes have it: The preservation of color vision in a creature of the night
9. Can brain-injured, partially-blind stroke patients regain some of their lost vision?
10. HEI, Inc. Closes on Sale of RFID Division Assets
11. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... ... 2016 , ... The Florida Hospital Tampa Wound Healing Institute ... (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute as ... facilities have earned this distinction. This is the second time the Florida Hospital ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician ... of Drug and Alcohol Programs Gary Tennis ... insomnia medications, known as benzodiazepines, developed with the ... "Benzodiazepines are medications that are frequently prescribed for ... they are used with opioid pain medications, benzodiazepines ...
(Date:12/8/2016)... 2016  A new study by a pair of ... opioid therapy to treat chronic pain is not only ... harmful consequences, including death. Palliative care physicians ... Mehta , M.D., authored the study which provides a ... The study was published in the December 2016 edition ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, LLC ... obtained proof-of-mechanism for neflamapimod (previously code named VX-745), ... 2a clinical trials that demonstrated significant Alzheimer,s disease ... (12-week treatment) and Study 303 (6-week treatment) are ... in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: